Browse the evidence

Elevated TNF-alpha expression in adipose tissue is associated with obesity and insulin resistance in humans, acting as a modulator of gene expression in adipocytes.

Obesity is associated with higher levels of TNF-alpha in fat tissue, which can worsen insulin resistance. This biological reality suggests that weight management may require addressing these underlying metabolic factors, not just calorie restriction.

Menstrual cycle phase (follicular vs. luteal) and oral contraceptive use (active vs. placebo) do not significantly influence substrate oxidation (carbohydrate and fat ratios) at rest or during moderate-intensity continuous exercise.

You do not need to adjust your carbohydrate or fat intake based on where you are in your menstrual cycle or whether you are on birth control. The science shows that fuel oxidation remains consistent across phases. Focus on consistent nutrition and training intensity rather than trying to 'hack' your cycle for metabolic changes.

Low baseline sympathoadrenal activity, indicated by low 24-hour urinary norepinephrine and epinephrine excretion rates, is associated with greater subsequent body weight gain and increased central adiposity (waist-to-thigh ratio) in humans.

If you have a history of easy weight gain, your body may naturally operate with lower sympathetic nervous system activity, which reduces energy expenditure and promotes fat storage, particularly around the waist. This is a biological predisposition, not a failure of will. To counter this, you may need to be more consistent with physical activity and dietary management than others, as your body is less efficient at burning off excess calories at rest.

Obesity reduces the accuracy of standard asthma biomarkers (FeNO, IgE, eosinophils), potentially leading to misclassification of asthma phenotype and inappropriate biologic eligibility.

If you have obesity, your standard asthma tests (FeNO, IgE) might look lower than they actually are. This doesn't mean your asthma is mild. Doctors should interpret these tests with caution in obese patients and focus on symptom control and quality of life.

Low-dose exposure to persistent organic pollutants (POPs) increases the risk of type 2 diabetes (T2D), primarily through mechanisms involving beta-cell dysfunction and mitochondrial toxicity rather than solely through insulin resistance.

You cannot completely avoid environmental pollutants like PCBs or pesticides, but you can manage their impact. Focus on healthy lifestyle behaviors like regular exercise and calorie restriction, which help eliminate POPs and improve mitochondrial function, thereby reducing your risk of developing type 2 diabetes.

Adipose tissue acts as a double-edged sword regarding POPs: it protects organs by sequestering POPs when healthy, but releases them into circulation during uncontrolled lipolysis (common in obesity or weight loss), increasing toxicity to other organs.

If you are overweight, be aware that rapid weight loss can temporarily spike the levels of environmental toxins in your blood as they are released from fat stores. Focus on gradual weight loss through exercise and a diet rich in phytochemicals, which helps your body eliminate these toxins more effectively.

The central nervous system (CNS) acts as a fundamental regulator of glucose homeostasis by establishing a biologically defended level of glycemia (BDLG), and dysfunction in CNS control mechanisms contributes to the pathogenesis of type 2 diabetes (T2D) independently of pancreatic beta cell failure.

Current diabetes treatments often fail to achieve long-term remission because they only address insulin levels, ignoring the brain's role in setting a 'defended' high blood sugar level. Effective management may require strategies that address central nervous system regulation of glucose, not just pancreatic insulin output.

Lower baseline beta cell function (measured by postprandial C-peptide index) is strongly associated with poorer glycemic control, higher HbA1c, and greater glycemic variability, regardless of whether the patient is treated with oral agents or insulin.

Your body's remaining ability to make insulin is the best predictor of how well your diabetes will be controlled. Even if you take medication, if your beta cells are failing, your blood sugar will be harder to manage. This highlights why preserving beta cell function is critical.

Fasting plasma adropin concentrations are positively correlated with fat consumption (total and saturated) and negatively correlated with carbohydrate intake as a percentage of total energy in human females.

This research identifies a strong statistical link between higher fasting levels of the hormone adropin and a preference for high-fat diets in lean women. It does not prove that high fat intake causes high adropin, or vice versa. For women, this suggests a biological underpinning to fat preference that may be distinct from men. It does not currently offer a direct intervention protocol, but highlights adropin as a potential biomarker for dietary macronutrient selection.

Hypertension and hyperlipidemia prevalence increases significantly with age, reaching 56% and 45% respectively in the elderly (≥65 years), indicating that age is a critical modifier for cardiovascular risk.

The risk of high blood pressure and high cholesterol rises sharply as you age, affecting more than half of the elderly population. However, these risks start rising in middle age. Regular monitoring and maintaining a healthy diet and activity level can help manage these risks at any age, not just in old age.

At physiological concentrations, insulin has a negligible thermic effect on its own; the majority of the thermic response to glucose/insulin infusions is driven by glucose metabolism (uptake, oxidation, and storage).

When you eat carbohydrates, the energy cost of processing them (thermic effect) is mostly due to the glucose being stored or oxidized, not the insulin released. While high insulin levels can slightly boost metabolism via the sympathetic nervous system, this effect is small at normal physiological levels. Focus on the total energy cost of nutrient processing rather than blaming insulin alone for metabolic inefficiency.

Higher central adiposity (measured by waist-to-hip ratio) causally increases the risk of kidney stone disease, mediated in part by elevated serum calcium concentrations.

Maintaining a healthy waist circumference is more critical for preventing kidney stones than general weight loss alone. Central fat raises serum calcium, which increases stone risk. Focus on reducing visceral fat through lifestyle changes to lower this specific biochemical risk.

Acute intravenous administration of the non-specific beta-adrenergic agonist isoproterenol does not increase mitochondrial protein synthesis or markers of mitochondrial biogenesis in resting adult men.

Taking beta-agonists or experiencing acute stress does not directly build mitochondrial density in your muscles. While beta-blockers might blunt some training adaptations, simply stimulating the beta-receptors acutely is not a strategy to increase mitochondrial biogenesis in humans. Focus on established stimuli like endurance exercise for mitochondrial health.

In patients with type 2 diabetes, elevated serum leptin levels are an independent predictor of ischemic heart disease incidence, providing prognostic value beyond traditional risk factors and non-invasive vascular markers.

For individuals with Type 2 Diabetes, high leptin levels signal a higher risk for heart disease, independent of weight or cholesterol. While leptin testing is not yet standard, managing inflammation and metabolic health remains critical. This data supports the importance of comprehensive cardiovascular risk assessment beyond just blood pressure and lipids.

Laparoscopic sleeve gastrectomy significantly reduces plasma Total Antioxidant Capacity (TAC), Total Oxidant Status (TOS), and DPPH radical-scavenging activity in morbidly obese patients over a 12-month period, indicating a restoration of redox homeostasis.

For morbidly obese individuals, bariatric surgery like sleeve gastrectomy significantly improves the body's antioxidant and oxidant balance over the first year, potentially reducing long-term health risks associated with oxidative stress. This benefit is achieved alongside strict adherence to post-operative dietary guidelines, including caloric restriction and specific vitamin supplementation.

While BAT activation does not cause weight loss, it may improve insulin sensitivity and glucose metabolism in humans.

If you have detectable brown fat, cold exposure might improve your insulin sensitivity and glucose metabolism, even if it doesn't help you lose weight.

Type 2 diabetic patients tend to experience a progressive decline in average body weight during the first 6 years after diagnosis, resulting in an average loss of 2.5 kg.

After being diagnosed with type 2 diabetes, it is common to lose an average of 2.5 kg over the next 6 years. This is often due to lifestyle changes and the physiological effects of the disease and treatment. This weight loss can be beneficial for your cardiovascular health.

Elevated GDF15 plasma levels are not a causal factor in cardiometabolic diseases such as obesity, type 2 diabetes, or cardiovascular disease, but rather serve as a biomarker of metabolic stress.

Do not rely on GDF15 levels to predict or treat obesity directly. While high GDF15 is a strong warning sign for heart disease and mortality, increasing it artificially (as done in animal studies) does not appear to cause weight loss in humans. Focus on established metabolic health markers instead.

Higher Body Mass Index (BMI) causally increases GDF15 plasma levels, identifying BMI as a driver of GDF15 elevation rather than the reverse.

High GDF15 is a consequence of higher body weight, not the cause. Managing BMI is the primary lever; GDF15 levels will naturally decrease as metabolic stress is reduced.

Obeticholic acid (25 mg/day) improves liver fibrosis in patients with MASH and stage 2-3 fibrosis, but does not significantly resolve MASH activity compared to placebo.

Obeticholic acid (25 mg daily) can significantly improve liver scarring (fibrosis) in patients with advanced MASH, but it does not reliably eliminate the inflammation (MASH) itself. The main barrier is itching (pruritus). This treatment is for specific high-risk patients, not general MASLD.

Pioglitazone (PPAR-gamma agonist) resolves MASH and reduces fibrosis stage, but its use is limited by adverse effects including fluid retention, weight gain, and osteopenia.

Pioglitazone can resolve MASH and reduce liver scarring, but it causes weight gain and fluid retention, which can worsen heart failure risk. It is generally limited by these side effects, particularly in older women due to fracture risk.

GIP receptor antagonism, specifically via the peptide GIP(3-30)NH2, increases GIP receptor surface expression and prevents internalization, thereby resensitizing the receptor for subsequent activation by endogenous or exogenous agonists.

Blocking the GIP receptor with specific antagonists like GIP(3-30)NH2 doesn't just turn off the signal; it keeps the receptors on the cell surface ready to receive signals. This resensitization may help overcome the impaired GIP response often seen in type 2 diabetes and obesity, potentially enhancing the effects of other treatments like GLP-1 agonists.

Metformin does not improve insulin-stimulated glucose uptake (insulin sensitivity) in individuals with type 2 diabetes; its primary mechanism is the suppression of lipolysis and reduction of free fatty acids, which enhances basal glucose clearance.

If you are taking metformin, do not expect it to 'fix' your insulin resistance in the sense of making your muscles more efficient at using insulin. Instead, it works by reducing the fat acids in your blood, which helps your body manage blood sugar at rest. This distinction is important for understanding why your insulin levels might drop without a corresponding change in how your muscles respond to high insulin levels.

Waist circumference does not predict insulin resistance better than body mass index (BMI); both measures are similarly correlated with insulin resistance.

You do not need to obsess over your waist circumference as a superior health metric. Your BMI is just as good at predicting your risk for insulin resistance. Focus on maintaining a healthy weight overall rather than trying to optimize one specific body measurement.